| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.EJPHAR.2013.03.007 |
| P8608 | Fatcat ID | release_tnmxqmoqbfbqtl5snp5qbz63n4 |
| P932 | PMC publication ID | 3759565 |
| P698 | PubMed publication ID | 23524089 |
| P2093 | author name string | W Brooks Gentry | |
| Alison Oliveto | |||
| Christopher Cargile | |||
| J Benjamin Guise | |||
| Warren Bickel | |||
| Nichole Sanders | |||
| Michael Mancino | |||
| P2860 | cites work | Buprenorphine for the management of opioid withdrawal | Q24240149 |
| Methadone at tapered doses for the management of opioid withdrawal | Q24246574 | ||
| Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers | Q31945536 | ||
| Opioid dependence treatment: options in pharmacotherapy | Q33868638 | ||
| Identification of a phenylalkylamine binding region within the alpha 1 subunit of skeletal muscle Ca2+ channels | Q33906282 | ||
| Pharmacokinetics and pharmacodynamics of two formulations of verapamil | Q34417142 | ||
| Alpha2-adrenergic agonists in opioid withdrawal | Q34564590 | ||
| Molecular mechanisms of drug addiction | Q35229411 | ||
| Neuropharmacology of cocaine and ethanol dependence | Q35255623 | ||
| Pharmacologic treatments for opioid dependence: detoxification and maintenance options | Q35454866 | ||
| A survey of chronic noncancer pain patients prescribed opioid analgesics. | Q35642552 | ||
| Dihydropyridine receptor of L-type Ca2+ channels: identification of binding domains for [3H](+)-PN200-110 and [3H]azidopine within the alpha 1 subunit. | Q37634992 | ||
| Calcium channel antagonists. Part IV: Side effects and contraindications drug interactions and combinations | Q39613008 | ||
| Mechanism of Action of Calcium-Channel-Blocking Agents | Q40131998 | ||
| Multiple Mechanisms of withdrawal from Opioid Drugs | Q40141461 | ||
| Role of calcium in morphine dependence and naloxone-precipitated withdrawal in mice | Q41350890 | ||
| Calcium channel inhibitors suppress the morphine-withdrawal syndrome in rats | Q41898927 | ||
| The severity of naloxone-precipitated opiate withdrawal is attenuated by felbamate, a possible glycine antagonist | Q42554846 | ||
| Effect of clonidine, nimodipine and diltiazem on the in vitro opioid withdrawal response in the guinea-pig ileum | Q42562002 | ||
| Safety of controlled-onset extended-release verapamil in middle-aged and older patients with hypertension and coronary artery disease | Q43805515 | ||
| Butorphanol and nalbuphine in opioid-dependent humans under a naloxone discrimination procedure | Q43867221 | ||
| Prolonged morphine treatment increases rat brain dihydropyridine binding sites: possible involvement in development of morphine dependence | Q43977777 | ||
| Divergent Effects of Dihydropyridine and Phenylalkylamine Calcium Channel Antagonist Classes on Autonomic Function in Human Hypertension | Q44297235 | ||
| Three-choice drug discrimination in opioid-dependent humans: hydromorphone, naloxone and saline. | Q44339441 | ||
| Clonidine and yohimbine in opioid-dependent humans responding under a naloxone novel-response discrimination procedure | Q44340986 | ||
| Direct evidence for a role of glutamate in the expression of the opioid withdrawal syndrome | Q44342103 | ||
| D-cycloserine-Naloxone interactions in opioid-dependent humans under a novel-response naloxone discrimination procedure | Q44342667 | ||
| Inhibitory effects of diltiazem, an L-type Ca2+ channel blocker, on naloxone-increased glutamate levels in the locus coeruleus of opioid-dependent rats | Q44342967 | ||
| Hydromorphone-naloxone combinations in opioid-dependent humans under a naloxone novel-response discrimination procedure | Q44348878 | ||
| Success and failure at outpatient opioid detoxification. Evaluating the process of clonidine- and methadone-assisted withdrawal | Q44350614 | ||
| Inhibition of reinforcing effects of morphine and naloxone-precipitated opioid withdrawal by novel glycine site and uncompetitive NMDA receptor antagonists | Q44350688 | ||
| Effects of three different L-type Ca2+ entry blockers on airway constriction induced by muscarinic receptor stimulation | Q44405020 | ||
| Clonidine and nifedipine inhibit the abstinence but not the development of dependence in isolated guinea pig ileum | Q44481690 | ||
| Suppression by ketamine and dextromethorphan of precipitated abstinence syndrome in rats | Q44550743 | ||
| Withdrawal-induced activation of locus coeruleus neurons in opiate-dependent rats: attenuation by lesions of the nucleus paragigantocellularis | Q44740867 | ||
| Isradipine and dextromethorphan in methadone-maintained humans under a naloxone discrimination procedure. | Q44894276 | ||
| 1,5-benzothiazepine binding domain is located on the extracellular side of the cardiac L-type Ca2+ channel | Q46485862 | ||
| NMDA receptor antagonists suppress behaviors but not norepinephrine turnover or locus coeruleus unit activity induced by opiate withdrawal | Q46686416 | ||
| Calcium channel blocking drugs in the management of drug dependence, withdrawal and craving. A clinical pilot study with nifedipine and verapamil. | Q47615996 | ||
| Clinical pharmacokinetics of vasodilators. Part I. | Q47913024 | ||
| Effect of nimodipine, diltiazem and BAY K 8644 on the behavioural and neurochemical changes associated with naloxone-precipitated withdrawal in the rat. A comparison with clonidine | Q48391463 | ||
| Opiate withdrawal-induced hyperactivity of locus coeruleus neurons is substantially mediated by augmented excitatory amino acid input | Q48620820 | ||
| Dihydropyridine calcium channel antagonists disrupt migrating myoelectric complexes and counteract intestinal disorders associated with morphine withdrawal diarrhea. | Q51602081 | ||
| Effects of diazepam and hydromorphone in triazolam-trained humans under a novel-response drug discrimination procedure. | Q51638106 | ||
| Clinical results of the Verapamil in Hypertension and Atherosclerosis Study | Q61456809 | ||
| Short-acting NMDA receptor antagonist MRZ 2/576 produces prolonged suppression of morphine withdrawal in mice | Q63435895 | ||
| Differential effects of L-type calcium channel blockers and stimulants on naloxone-precipitated withdrawal in mice acutely dependent on morphine | Q67701864 | ||
| Acute conversion of paroxysmal supraventricular tachycardia with intravenous diltiazem. IV Diltiazem Study Group | Q68025049 | ||
| Clonidine in morphine withdrawal. Differential effects on signs and symptoms | Q68944527 | ||
| Effects of peripheral and central administration of calcium channel blockers in the naloxone-precipitated abstinence syndrome in morphine-dependent rats | Q69128878 | ||
| A novel-response procedure enhances the selectivity and sensitivity of a triazolam discrimination in humans | Q70537135 | ||
| Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man | Q71783769 | ||
| Diltiazem inhibits naloxone-precipitated and spontaneous morphine withdrawal in rats | Q71942968 | ||
| The effects of age and gender on the stereoselective pharmacokinetics of verapamil | Q72929846 | ||
| Competitive and glycine/NMDA receptor antagonists attenuate withdrawal-induced behaviours and increased hippocampal acetylcholine efflux in morphine-dependent rats | Q73326348 | ||
| Triazolam discrimination by humans under a novel response procedure: effects of buspirone and lorazepam | Q73553608 | ||
| Verapamil prevents withdrawal excitation of oxytocin neurones in morphine-dependent rats | Q73898232 | ||
| The current status of antihypertensive treatments: into the new millennium | Q93953357 | ||
| P433 | issue | 1-3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 424-435 | |
| P577 | publication date | 2013-03-21 | |
| P1433 | published in | European Journal of Pharmacology | Q1376712 |
| P1476 | title | Effects of prototypic calcium channel blockers in methadone-maintained humans responding under a naloxone discrimination procedure | |
| P478 | volume | 715 |
Search more.